Implementation of device therapy (cardiac resynchronization therapy and implantable cardioverter defibrillator) for patients with heart failure in Europe: changes from 2004 to 2008

Veldhuisen, Dirk J. van; Maass, Alexander H.; Priori, Silvia G.; Stolt, Pelle; Gelder, Isabelle C. Van; Dickstein, Kenneth; Swedberg, Karl

doi:10.1093/eurjhf/hfp149

Cited by 125 publications

(91 citation statements)

References 36 publications

(58 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Use of an implantable cardioverter-defibrillator was relatively infrequent, but this finding is similar to those in recent registries and trials. 24,25 The early stopping of the trial may have resulted in overestimation of the magnitude of the treatment effect, 26 but the results are consistent with those seen in RALES. 2 In conclusion, our study showed that, as compared with placebo, eplerenone added to recommended therapy for systolic heart failure in patients with mild symptoms was associated with a reduction in the rate of death from a cardiovascular cause or hospitalization for heart failure.…”

Section: Referencessupporting

confidence: 53%

Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms

McMurray²,

et al. 2011

Self Cite

View full text Add to dashboard Cite

Section: Referencessupporting

confidence: 53%

Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms

McMurray²,

et al. 2011

Self Cite

View full text Add to dashboard Cite

“…Większość dużych prób klinicznych z zastosowaniem leków w HF przeprowadzono przed ogłoszeniem pozytywnych wyników przełomowych prób klinicznych z użyciem ICD [63,64] i CRT [313,314] (2005 r.). Dowody z tych prób klinicznych zaowocowały silnym zaleceniem tych metod w wytycznych dotyczących HF, co spowodowało ogromny wzrost częstości ich stosowania [7,315].…”

Section: Ablacja Przezcewnikowaunclassified

2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death

Priori

Blomström‐Lundqvist²,

Mazzanti³

et al. 2015

Kardiol Pol

Self Cite

233

337

View full text Add to dashboard Cite

“…In Europe, and especially in Italy, CRT-D use is rising faster than the use of any of the other devices indicated for heart failure treatment. 13 In the light of the recent extension of European CRT recommendations to mildly symptomatic patients, 5 further growth can be expected. Recently, attention has been drawn to the number of ICD recipients who may not benefit from the device but are still exposed to procedural and device-related complications, raising the question of whether current complications of ICD therapy have been underestimated and the benefits overestimated.…”

Section: Discussionmentioning

confidence: 99%

Long-Term Complications Related to Biventricular Defibrillator Implantation

et al. 2011

View full text Add to dashboard Cite

on behalf of the Cardiovascular Centers Participating in the ClinicalService ProjectBackground-Long-term data on device-related untoward events in patients receiving defibrillators for resynchronization therapy (CRT-D) are lacking. We quantified the frequency of repeat invasive procedures and the nature of long-term complications in current clinical practice and examined possible predictors of device-related events and their association with long-term patient outcome. Methods and Results-We analyzed data from 3253 patients who underwent de novo successful implantation of CRT-D and were followed up for a median of 18 months (25th to 75th percentiles: 9 to 30) in 117 Italian centers. Device-related events were reported in 416 patients, and, specifically, surgical interventions for system revision were described in 390 patients. Four years after the implantation procedure, 50% of patients underwent surgical revision for battery depletion and 14% for unanticipated events. For comparison, at 4 years battery depletion occurred in 10% and 13% of patients who received single-and dual-chamber defibrillators at the study centers, and unanticipated events were reported as 4% and 9%, respectively. In CRT-D, infections occurred at a rate of 1.0%/y, and the risk of infections increased after device replacement procedures (hazard ratio, 2.04; 95% confidence interval, 1.01 to 4.09; Pϭ0.045). Left ventricular lead dislodgements were reported at a rate of 2.3%/y and were predicted by longer fluoroscopy time and higher pacing threshold on implantation. Device-related events were not associated with a worse clinical outcome; indeed, the risk of death was similar in patients with and without surgical revision (hazard ratio, 0.90; 95% confidence interval, 0.56 to 1.47; Pϭ0.682). Conclusions-In current clinical practice device-related events are more frequent in CRT-D than in single-or dual-chamber defibrillators, and are frequently managed by surgical intervention for system revision. However, a worse clinical outcome is not associated with these events. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01007474.

show abstract

Implementation of device therapy (cardiac resynchronization therapy and implantable cardioverter defibrillator) for patients with heart failure in Europe: changes from 2004 to 2008

Cited by 125 publications

References 36 publications

Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms

Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms

2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death

Long-Term Complications Related to Biventricular Defibrillator Implantation

Contact Info

Product

Resources

About